This implementation corrects that unauthorized coverage." [2] This means: Even if you had an approved PA before August 31 , it became invalid on that date You now pay 100% out of pocket for Wegovy, Zepbound, Saxenda, Qsymia, Phentermine, and Contrave if prescribed for weight loss No grandfathering the change applied immediately to all TFL beneficiaries What's Still Covered for TFL Diabetes Indication Still Covered GLP-1s prescribed for Type 2 diabetes (Ozempic, Mounjaro, Victoza) remain covered for TFL beneficiaries with prior authorization
The honest answer is uncomfortable
A battery label only tells part of the story
My GP said my TSH was 'normal', but I still feel like something is wrong." Here, a Gold Thyroid Blood Test might be more appropriate
Oral Non Peptide GLP 1 Receptor Agonist Market Size is valued at USD 102.77 Bn in 2025 and is predicted to reach USD 243.16 Bn by the year 2035 at a 9.2% CAGR during the forecast period for 2026 to 2035